| 秦智慧,林 楠,李绪东,曹 野,孙思维,蔡 雁.MiR-23a靶向HOXC8在黑龙江省宫颈癌人群中发生的作用分析[J].现代生物医学进展英文版,2020,(18):3466-3469. |
| MiR-23a靶向HOXC8在黑龙江省宫颈癌人群中发生的作用分析 |
| Analysis of the Role of MiR-23a Targeting HOXC8 in Patients with Cervical Cancer in Heilongjiang Province |
| Received:February 23, 2020 Revised:March 18, 2020 |
| DOI：10.13241/j.cnki.pmb.2020.18.014 |
| 中文关键词: 宫颈癌 黑龙江省 MiR-23a HOXC8 作用机制 |
| 英文关键词: Cervical cancer Heilongjiang province MiR - 23 a HOXC8 Mechanism of action |
| 基金项目:黑龙江省卫生计生委科研基金项目（ 2018322）；哈尔滨医科大学创新科学研究资助项目（2016版） |
| Author Name | Affiliation | E-mail | | QIN Zhi-hui | Department of obstetrics and gynecology, the fourth affiliated hospital of Harbin medical university, Harbin, Heilongjiang, 150001, China | 773575152@qq.com | | LIN Nan | Department of obstetrics and gynecology, the fourth affiliated hospital of Harbin medical university, Harbin, Heilongjiang, 150001, China | | | LI Xu-dong | Department of obstetrics and gynecology, the fourth affiliated hospital of Harbin medical university, Harbin, Heilongjiang, 150001, China | | | CAO Ye | Department of obstetrics and gynecology, the fourth affiliated hospital of Harbin medical university, Harbin, Heilongjiang, 150001, China | | | SUN Si-wei | Department of obstetrics and gynecology, the fourth affiliated hospital of Harbin medical university, Harbin, Heilongjiang, 150001, China | | | CAI Yan | Department of obstetrics and gynecology, the fourth affiliated hospital of Harbin medical university, Harbin, Heilongjiang, 150001, China | |
|
| Hits: 776 |
| Download times: 512 |
| 中文摘要: |
| 摘要 目的：研究MiR-23a靶向HOXC8在黑龙江省宫颈癌人群中发生的作用及机制。方法：采集从2017年1月～2019年1月，于我院确诊为正常宫颈、宫颈上皮内瘤变（CIN）、宫颈癌患者的病变组织各90例。采用逆转录多聚酶联反应（RT-PCR）法分别检测正常宫颈组织、CIN组织、宫颈癌组织中的MiR-23a表达水平。此外，通过Lipofectamine?3000转染试剂将MiR-23a模拟物、MiR-23a抑制物以及空白对照片段转染至宫颈癌细胞Siha中，检测转染后0 h、48 h、72 h时三组Siha细胞的增殖能力情况。另外，以RT-PCR法检测正常宫颈组织、CIN组织、宫颈癌组织中的HOXC8表达水平。结果：宫颈癌组织中MiR-23a的相对表达量显著高于CIN组织与正常组织，且CIN组织中MiR-23a的相对表达量显著高于正常组织（均P＜0.05）。MiR-23a模拟物组Siha细胞的增殖能力显著优于MiR-23a抑制物组与空白对照组，且空白对照组Siha细胞的增殖能力明显优于MiR-23a抑制物组（均P＜0.05）。宫颈癌组织中HOXC8的相对表达量显著高于CIN组织与正常组织，且CIN组织中HOXC8的相对表达量显著高于正常组织（均P＜0.05）。结论：MiR-23a可能是通过靶向下调HOXC8基因的表达，进一步促进了宫颈癌的发生、发展，这为临床宫颈癌的防治提供了新的靶点，值得临床重点关注。 |
| 英文摘要: |
| ABSTRACT Objective: To study the role and mechanism of MiR-23a targeting HOXC8 in cervical cancer population in heilongjiang province. Methods: From January 2017 to January 2019, 90 patients with normal cervical, cervical intraepithelial neoplasia (CIN) and cervical cancer were collected from our hospital. The expression levels of MiR-23a in normal cervical tissues, CIN tissues and cervical cancer tissues were detected by RT-PCR. In addition, Lipofectamine?3000 transfection reagent was used to transfect MiR-23a mimics, MiR-23a inhibitors and blank control fragments into cervical cancer cell Siha, and the proliferation capacity of the three groups of Siha cells was detected at 0h, 48h and 72h after transfection. In addition, the expression levels of HOXC8 in normal cervical tissues, CIN tissues and cervical cancer tissues were detected by RT-PCR. Results: The relative expression of MiR-23a in cervical cancer tissue was significantly higher than that in CIN tissue and normal tissue, and the relative expression of MiR-23a in CIN tissue was significantly higher than that in normal tissue (all P<0.05). The proliferation ability of Siha cells in the MiR-23a simulant group was significantly better than that in the MiR-23a inhibitor group and the blank control group, and the proliferation ability of Siha cells in the blank control group was significantly better than that in the MiR-23a inhibitor group (all P<0.05). The relative expression of HOXC8 in cervical cancer tissue was significantly higher than that in CIN tissue and normal tissue, and the relative expression of HOXC8 in CIN tissue was significantly higher than that in normal tissue (all P<0.05). Conclusion: MiR-23a may further promote the occurrence and development of cervical cancer by targeting and down-regulating the expression of HOXC8 gene, which provides a new target for the prevention and treatment of clinical cervical cancer and deserves clinical focus. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
